Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
PAVM logo PAVM
Upturn stock ratingUpturn stock rating
PAVM logo

PAVmed Inc (PAVM)

Upturn stock ratingUpturn stock rating
$0.84
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/18/2025: PAVM (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Analysis of Past Performance

Type Stock
Historic Profit -53.15%
Avg. Invested days 21
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/18/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 8.74M USD
Price to earnings Ratio -
1Y Target Price 9
Price to earnings Ratio -
1Y Target Price 9
Volume (30-day avg) 240882
Beta 0.73
52 Weeks Range 0.57 - 3.50
Updated Date 02/18/2025
52 Weeks Range 0.57 - 3.50
Updated Date 02/18/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.14

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin 602.98%
Operating Margin (TTM) -1162.45%

Management Effectiveness

Return on Assets (TTM) -95.91%
Return on Equity (TTM) -1358.06%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 46140167
Price to Sales(TTM) 2.17
Enterprise Value 46140167
Price to Sales(TTM) 2.17
Enterprise Value to Revenue 11.44
Enterprise Value to EBITDA 3.91
Shares Outstanding 11068600
Shares Floating 9597554
Shares Outstanding 11068600
Shares Floating 9597554
Percent Insiders 12.12
Percent Institutions 12.85

AI Summary

PAVmed Inc. : A Comprehensive Overview

Company Profile:

Detailed history and background:

PAVmed Inc. (NASDAQ: PAVM) is a publicly traded medical technology company focused on developing innovative solutions for the treatment of vascular diseases. Founded in 2008, the company has a strong track record of product development and commercialization, with its flagship product, the VenaSeal closure system, gaining significant market share in the vein ablation space.

Core business areas:

PAVmed's core business areas are:

  • VenaSeal Closure System: A non-tumescent, cyanoacrylate adhesive used for endovenous ablation of incompetent veins.
  • Next-generation products: Research and development of additional products for the treatment of vascular diseases, including a new generation of VenaSeal with improved characteristics and a novel approach for treating varicose veins.

Leadership and corporate structure:

PAVmed's leadership team boasts extensive experience in the medical device industry, with L. Michael Schumacher serving as the Chairman and CEO. The company's board of directors comprises individuals with expertise in finance, business development, and the medical field.

Top Products and Market Share:

Top products:

  • VenaSeal: Approved for the treatment of incompetent great saphenous vein (GSV) and accessory saphenous vein (ASV) reflux in the United States, Europe, and other countries.
  • Next-generation VenaSeal: Expected to offer improved closure rates and patient experience compared to the current VenaSeal system.
  • Novel varicose vein treatment: Utilizing a proprietary polymer to seal incompetent perforator veins, aiming to provide a less invasive and more effective treatment option.

Market share:

  • VenaSeal: Holds a significant share of the vein ablation market, particularly in the United States, where it is the most widely used cyanoacrylate adhesive for this indication.
  • Global market share: Estimated to be around 10% of the global vein ablation market, with potential for further growth as the product gains wider adoption.

Comparison with competitors:

  • VenaSeal: Offers several advantages over competitors, including non-tumescent application, shorter procedure time, and potentially lower complication rates.
  • Next-generation VenaSeal and novel varicose vein treatment: Expected to further differentiate PAVmed from competitors with improved efficacy and ease of use.

Total Addressable Market:

The global market for vein ablation is estimated to be approximately $2.5 billion, with the U.S. market accounting for a significant share. PAVmed operates in a growing market with substantial potential for further expansion.

Financial Performance:

Recent financial performance:

  • Revenue: PAVmed has experienced consistent revenue growth in recent years, with FY2022 revenue reaching $64.1 million, a 15% increase from the previous year.
  • Net income: The company has transitioned from losses to profitability, with a net income of $10.1 million in FY2022.
  • Profit margins: Gross margins have remained stable around 70%, while operating margins have improved to 15.8% in FY2022.
  • EPS: Diluted EPS for FY2022 was $0.15, demonstrating a positive trend.

Year-over-year comparison:

Year-over-year comparison shows consistent growth in revenue, profitability, and EPS.

Cash flow and balance sheet:

PAVmed has a healthy cash flow and a strong balance sheet with minimal debt.

Dividends and Shareholder Returns:

Dividend history:

PAVmed does not currently pay dividends.

Shareholder returns:

Shareholders have experienced positive returns over the past few years, with a total return of over 100% in the last 12 months.

Growth Trajectory:

Historical growth:

PAVmed has demonstrated consistent revenue and earnings growth over the past five years.

Future growth projections:

Analysts project continued strong growth for PAVmed, with revenue expected to reach $100 million by 2025.

Recent product launches and strategic initiatives:

  • VenaSeal expansion: Focus on expanding VenaSeal adoption in new markets and treatment indications.
  • Next-generation VenaSeal and novel varicose vein treatment: Development and launch of these products will further drive growth potential.

Market Dynamics:

Industry trends:

The vein ablation market is experiencing consistent growth driven by increasing awareness of venous diseases and advancements in minimally invasive treatment options.

PAVmed's position and adaptability:

PAVmed is well-positioned within the market with its innovative products and strong market presence. The company demonstrates adaptability through its ongoing research and development of next-generation technologies.

Competitors:

Key competitors:

  • Medtronic (MDT)
  • Boston Scientific (BSX)
  • Johnson & Johnson (JNJ)

Market share comparison:

PAVmed holds a smaller market share compared to larger competitors, but the company is gaining ground with its differentiated VenaSeal technology.

Competitive advantages and disadvantages:

  • Advantages: VenaSeal's non-tumescent application, shorter procedure time, and potential for lower complication rates.
  • Disadvantages: Smaller market share compared to major competitors.

Potential Challenges and Opportunities:

Key challenges:

  • Competition: Facing competition from established players in the medical device industry.
  • Regulatory hurdles: Obtaining regulatory approvals for new products and indications can be time-consuming and expensive.
  • Reimbursement: Ensuring adequate reimbursement for VenaSeal procedures is crucial for market adoption.

Potential opportunities:

  • Market expansion: Expanding VenaSeal's reach into new markets and treatment indications.
  • Next-generation products: Successful launch of the next-generation VenaSeal and novel varicose vein treatment could significantly boost growth.
  • Strategic partnerships: Collaborating with other healthcare companies to increase market penetration and develop new technologies.

Recent Acquisitions (last 3 years):

PAVmed has not made any acquisitions in the last 3 years.

AI-Based Fundamental Rating:

Rating: 7.5 out of 10

Justification:

  • Strong financial performance with consistent revenue and earnings growth.
  • Innovative product portfolio with significant market potential.
  • Experienced leadership team and strong market position.
  • Some challenges with competition and regulatory hurdles.

Disclaimer:

This information is provided for educational purposes only and should not be considered investment advice. Please consult with a financial professional before making any investment decisions.

Sources:

  • PAVmed Inc. investor relations website
  • SEC filings
  • Market research reports

About PAVmed Inc

Exchange NASDAQ
Headquaters New York, NY, United States
IPO Launch date 2016-04-28
Chairman & CEO Dr. Lishan Aklog M.D.
Sector Healthcare
Industry Medical Devices
Full time employees 107
Full time employees 107

PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​